BIO-RAD LABORATORIES, INC. Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss
BIO-RAD LABORATORIES, INC. (BIO.B) reported Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$1.68 billion for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2024-10-31
- BIO-RAD LABORATORIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-09-30 was $792.90M, a 2072.33% increase year-over-year.
- BIO-RAD LABORATORIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-06-30 was -$2.90B.
- BIO-RAD LABORATORIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-03-31 was $422.20M.
- BIO-RAD LABORATORIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-12-31 was $324.20M, a 66.87% decline year-over-year.
- BIO-RAD LABORATORIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was -$1.25B.
- BIO-RAD LABORATORIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was -$5.19B, a 205.43% decline from fiscal 2021.
- BIO-RAD LABORATORIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2021 was $4.93B, a 9.57% increase from fiscal 2020.
- BIO-RAD LABORATORIES, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2020 was $4.50B, a 121.36% increase from fiscal 2019.
| Period end | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2024-09-30 | $792.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$2.10B derived: sum of 2 quarters · filed 2024-10-31 | -$1.68B 10-Q · filed 2024-10-31 | -$1.36B derived: sum of 4 quarters · filed 2024-10-31 |
| 2024-06-30 | -$2.90B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$2.47B 10-Q · filed 2024-08-02 | -$2.15B derived: sum of 3 quarters · filed 2024-08-02 | -$2.11B derived: sum of 4 quarters · filed 2024-10-31 |
| 2024-03-31 | $422.20M 10-Q · filed 2024-05-08 | $746.40M derived: sum of 2 quarters · filed 2024-05-08 | $782.90M derived: sum of 3 quarters · filed 2024-10-31 | -$812.60M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-12-31 | $324.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $360.70M derived: sum of 2 quarters · filed 2024-10-31 | -$1.23B derived: sum of 3 quarters · filed 2024-10-31 | -$1.25B 10-K · filed 2024-02-16 |
| 2023-09-30 | $36.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$1.56B derived: sum of 2 quarters · filed 2024-10-31 | -$1.58B 10-Q · filed 2024-10-31 | -$597.80M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | -$1.60B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$1.61B 10-Q · filed 2024-08-02 | -$634.30M derived: sum of 3 quarters · filed 2024-08-02 | -$923.30M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | -$17.50M 10-Q · filed 2024-05-08 | $961.20M derived: sum of 2 quarters · filed 2024-05-08 | $672.20M derived: sum of 3 quarters · filed 2024-05-08 | -$666.00M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $978.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $689.70M derived: sum of 2 quarters · filed 2024-02-16 | -$648.50M derived: sum of 3 quarters · filed 2024-02-16 | -$5.19B 10-K · filed 2024-02-16 |
| 2022-09-30 | -$289.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-27 | -$1.63B derived: sum of 2 quarters · filed 2023-10-27 | -$6.17B 10-Q · filed 2023-10-27 | -$8.32B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-06-30 | -$1.34B derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$5.88B 10-Q · filed 2023-08-04 | -$8.04B derived: sum of 3 quarters · filed 2024-02-16 | -$3.17B derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-03-31 | -$4.55B 10-Q · filed 2023-05-05 | -$6.70B derived: sum of 2 quarters · filed 2024-02-16 | -$1.83B derived: sum of 3 quarters · filed 2024-02-16 | -$798.30M derived: sum of 4 quarters · filed 2024-02-16 |
| 2021-12-31 | -$2.15B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $2.72B derived: sum of 2 quarters · filed 2024-02-16 | $3.75B derived: sum of 3 quarters · filed 2024-02-16 | $4.93B 10-K · filed 2024-02-16 |
| 2021-09-30 | $4.87B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $5.90B derived: sum of 2 quarters · filed 2022-10-28 | $7.08B 10-Q · filed 2022-10-28 | $7.98B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $1.03B derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $2.21B 10-Q · filed 2022-07-29 | $3.11B derived: sum of 3 quarters · filed 2023-02-17 | $4.69B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $1.18B 10-Q · filed 2022-04-29 | $2.08B derived: sum of 2 quarters · filed 2023-02-17 | $3.66B derived: sum of 3 quarters · filed 2023-02-17 | $4.85B derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $904.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $2.48B derived: sum of 2 quarters · filed 2023-02-17 | $3.67B derived: sum of 3 quarters · filed 2023-02-17 | $4.50B 10-K · filed 2023-02-17 |
| 2020-09-30 | $1.58B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $2.76B derived: sum of 2 quarters · filed 2021-10-29 | $3.59B 10-Q · filed 2021-10-29 | $4.24B derived: sum of 4 quarters · filed 2022-02-11 |
| 2020-06-30 | $1.18B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $2.01B 10-Q · filed 2021-07-30 | $2.66B derived: sum of 3 quarters · filed 2022-02-11 | $2.27B derived: sum of 4 quarters · filed 2022-02-11 |
| 2020-03-31 | $827.70M 10-Q · filed 2021-04-30 | $1.47B derived: sum of 2 quarters · filed 2022-02-11 | $1.08B derived: sum of 3 quarters · filed 2022-02-11 | $1.80B derived: sum of 4 quarters · filed 2022-02-11 |
| 2019-12-31 | $646.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11 | $255.40M derived: sum of 2 quarters · filed 2022-02-11 | $971.80M derived: sum of 3 quarters · filed 2022-02-11 | $2.03B 10-K · filed 2022-02-11 |
| 2019-09-30 | -$390.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $325.80M derived: sum of 2 quarters · filed 2020-10-30 | $1.39B 10-Q · filed 2020-10-30 | $570.90M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $716.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $1.78B 10-Q · filed 2020-07-31 | $961.50M derived: sum of 3 quarters · filed 2021-02-16 | $1.28B derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $1.06B 10-Q · filed 2020-05-08 | $245.10M derived: sum of 2 quarters · filed 2021-02-16 | $563.10M derived: sum of 3 quarters · filed 2021-02-16 | $849.50M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | -$814.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | -$496.10M derived: sum of 2 quarters · filed 2021-02-16 | -$209.70M derived: sum of 3 quarters · filed 2021-02-16 | $606.20M 10-K · filed 2021-02-16 |
| 2018-09-30 | $318.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $604.40M derived: sum of 2 quarters · filed 2019-11-01 | $1.42B 10-Q · filed 2019-11-01 | $1.42B derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $286.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.10B 10-Q · filed 2019-08-06 | $1.10B derived: sum of 3 quarters · filed 2020-03-02 | $1.10B derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $815.90M 10-Q · filed 2019-05-10 | $815.90M derived: sum of 2 quarters · filed 2020-03-02 | $815.90M derived: sum of 3 quarters · filed 2020-03-02 | $815.90M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $0.00 derived: sum of 2 quarters · filed 2018-11-05 | $0.00 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $0.00 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-04-01 |